

March 9, 2016

To Whom It May Concern

Company: Taisho Pharmaceutical Holdings Co., Ltd.
Representative: Akira Uehara, President and CEO
Stock code: 4581 (TSE First Section)
Contact: Takashi Shibata, General Manager
Corporate Communications
(Tel: +81-3-3985-1115)

**Status of Stock Buyback on Open Market,
End of Buyback Program**
**(Treasury stock repurchase based on the Articles of Incorporation
as stipulated by Article 165, Paragraph 2 of the Japanese Corporation Act)**

Taisho Pharmaceutical Holdings Co., Ltd. has announced that it has repurchased treasury stock on the open market, as detailed below. This acquisition was based on the provisions of Article 156 of the Japanese Corporation Act, which has been reinterpreted and applied in accordance with Article 165, Paragraph 3 of the same Act. With this buyback, Taisho Pharmaceutical Holdings has completed the acquisition of all its own shares approved by the Board of Directors on February 3, 2016 in accordance with the aforementioned regulations.

1. Type of stock: Taisho Pharmaceutical Holdings common stock
2. Period of repurchase: From March 1, 2016 to March 8, 2016
(execution basis)
3. Amount of stock: 303,900 shares
4. Total value of stock: ¥ 2,761,051,000
5. Method of repurchase: On the open market through the Tokyo Stock Exchange

Notes:

1. Details of Board of Directors resolution about repurchase on February 3, 2016
 - Type of stock: Taisho Pharmaceutical Holdings common stock
 - Amount of stock: 1,500,000 shares (upper limit)
(percentage of total number shares issued*: 1.85%)
*excluding treasury stocks
 - Total value of stock: ¥ 10,000 million (upper limit)
 - Period of repurchase: From February 9, 2016 to May 31, 2016
2. Cumulative common stock repurchased to date since above Board of Directors' resolution (as of March 8, 2016)
 - Amount of stock: 1,152,200 shares
 - Total value of stock: ¥ 9,999,503,000